Bone Biologics Corporation
BBLGRating Trend
Earnings History
Next report: Mar 1, 2027 · EPS est. $-0.15| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 26, 2026 | $-0.17 | $-0.19 | — | — |
| Aug 14, 2026 | $-0.43 | $-0.43 | — | — |
| May 14, 2026 | $-0.43 | $-0.43 | — | — |
| Mar 2, 2026 | $-0.58 | $-0.34 | — | — |
| Nov 14, 2025 | $-0.37 | $-1.23 | — | — |
| Aug 14, 2025 | $-1.33 | $-0.58 | — | — |
| May 13, 2025 | $-0.32 | $-3.24 | — | — |
| Mar 5, 2025 | $-0.48 | $-0.65 | — | — |
News
Bone Biologics Corp. (NASDAQ: BBLG - Get Free Report) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totaling 36,999 shares, a decrease of 76.4% from the August 15th total of 156,590 shares. Approximately 1.4% of the shares of the stock are sold short. Based
BURLINGTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced that six hospital sites in Australia are now under agreement to participate in its first-in-human pilot clinical trial of NB1, the Company's rhNELL-1-based bone graft product for spinal fusion.
BURLINGTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.
BURLINGTON, Mass, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announces that the validated shelf life of its rhNELL-1 protein has been extended to 32 months. “Reaching a 32-month validated shelf life gives us greater flexibility in how we manufacture, store and distribute rhNELL-1 as we prepare for pivotal-study scale,” said Jeff Frelick, Chief Executi…